Inclinix, a US-based contract research organisation (CRO) that provides customised solutions for patient enrolment to Phase I-IV clinical trials, has raised its profile in Eastern and Western Europe through a formal strategic partnership with JSW Life Sciences, a full-service CRO based in Austria and specialising in diseases of the central nervous system.
The partnership gives Inclinix offices in Graz, Austria and an expanded team that includes more than 100 enrolment professionals in Eastern and Western Europe. President and chief executive officer J. Tobin Geatz pointed to the company’s “significant growth” over the past year, which made it “important for us to identify a European partner that shares our philosophy and performance enrolment model”.
Inclinix’s Clinical Enrollment Manager (CEM) programmes provide in-field support to investigative sites conducting clinical trials. The CEMs seek to identify suitable study candidates not only from within the sites’ practices but from the surrounding medical and patient communities as well. JSW’s preclinical research department focuses on drug development for neurodegenerative diseases, while its clinical research team handles anything from first-in-human Phase I trials through to post-marketing surveillance studies.